Biogen shares soar on Alzheimer's drug developments
September 28, 2022 at 10:16 AM EDT
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|